文献速递临床试验与 GCP

中西医结合治疗重症社区获得性肺炎:随机安慰剂对照试验方案

Integrated traditional Chinese and conventional medicine in treatment of severe community-acquired pneumonia: study protocol for a randomized placebo-controlled trial.
PubMed 文献 · Trials · 2018-11-12

该研究为前瞻性、多中心、单盲、双模拟、随机对照试验,计划纳入198例重症社区获得性肺炎患者,比较常规药物联合中药与单用常规药物的疗效。中药每日两次给药28天,随访3个月,主要结局为治疗失败(临床恶化)。

要点

  • 中药联合常规药物可能降低治疗失败、临床稳定时间、住院时长和院内死亡率。
  • 主要结局为治疗失败,定义为临床恶化。
  • 试验采用双模拟设计,随访3个月。

核心结论

  • 假设常规药物联合中药可降低重症社区获得性肺炎患者的治疗失败、临床稳定时间、住院时长和院内死亡率,并改善生活质量。

研究设计与样本

  • 前瞻性、多中心、单盲、双模拟、随机对照试验,计划纳入198例重症社区获得性肺炎患者,每组99例。

关键数值与推荐

  • 中药每日两次给药,持续28天,所有患者随访3个月。
  • 主要结局为治疗失败,定义为临床恶化。
  • 次要结局包括临床稳定时间、住院时长、院内死亡率、SOFA问卷、生活质量和治疗费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Community-acquired pneumonia, especially severe community-acquired pneumonia (SCAP), remains the leading cause of death in the world. Despite advances in antimicrobial therapy, the mortality rates due to SCAP have not decreased significantly since antibiotics became routinely available. Traditional Chinese medicine (TCM) has been used for treating pneumonia for thousands of years. It is popular and widely practiced in Asia. In recent decades, evidence from both clinicians and patients suggests that TCM has some beneficial effect on SCAP. Thus, this study aims to compare the efficacy of a combination of a conventional drug and TCM to the conventional drug alone, to provide a scientific basis for clinical decisions. METHODS/DESIGN: A prospective, multi-center, single-blinded, double-dummy, and randomized controlled clinical trial is being conducted to test the therapeutic effects of a combination of conventional medicine and TCM versus conventional medicine in the treatment of SCAP. A total of 198 patients will be enrolled in this study, with 99 in each treatment group (combination group or conventional medicine group). The TCM will be administered twice daily for 28 days. All patients will be followed for 3 months. The primary outcome measure is treatment failure, which is defined as clinical deterioration. Secondary outcome measures are time to clinical stability, length of hospital stay, in-hospital mortality, SOFA questionnaire, quality of life and cost of treatment. DISCUSSION: It is hypothesized that the combination of a conventional drug and TCM will reduce treatment failure, time to clinical stability, length hospital of stays, and in-hospital mortality, and improve the quality of life of SCAP patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03185923 . Registered on 20 June 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang H, Li J, Yu X, et al. Integrated traditional Chinese and conventional medicine in treatment of severe community-acquired pneumonia: study protocol for a randomized placebo-controlled trial. Trials. 2018. PMID: 30419961. doi:10.1186/s13063-018-3005-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。